Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 1371 results for patients and public

  1. Data collection agreement

    treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for...

  2. How we develop medical technologies guidance

    wk0 Scope prepared The scope defines the: disease(s) patients and technology covered by the assessment questions the guidance aims to

  3. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  4. Single technology appraisal (STA) timeline

    A step-by-step timeline of the process we used to develop single technology appraisals (STA)

  5. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (IPG766)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  6. Public involvement - putting you at the heart of our work

    advice. We're committed to involving people who use services, carers and the public in the development of our guidance and other...

  7. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  8. Management of inflammatory arthritis

    biosimilar version. This may suggest differing perspectives from clinicians and patients on the level of support and information...

  9. MTA process timeline

    take part in the appraisal and to nominate clinical, commissioning and patient experts . We ask consultees to submit any relevant...

  10. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

  11. NICE decision aid: process guide (PMG42)

    NICE decision aid: process guide

  12. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

  13. Quality standards advisory committee 3 members

    Find out more about quality standards advisory committee 3 members at NICE.

  14. About

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer. We do this by:...

  15. Alcohol use: brief intervention for people with a long-term condition (IND202)

    This indicator covers the percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM181

  16. Alcohol use: risk assessment for people with a long-term condition (IND201)

    This indicator covers the percentage of patients with 1 or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the preceding 2 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM180

  17. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries (IPG762)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. This involves keyhole abdominal surgery. The aim is to stimulate and possibly strengthen the diaphragm to help people breathe without a ventilator.

  18. Terms and conditions

    Terms and conditions for the National Institute for Health and Care Excellence

  19. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  20. STA process timeline, pre-April 2018

    These are the main stages in the single technology appraisal (STA) process used before April 2018.

  21. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  22. NICE medicines and prescribing associates

    Our associates help us to support and promote high quality, safe, cost-effective prescribing and medicines optimisation.

  23. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTE7)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing....

  24. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    Guide to the technology appraisal and highly specialised technologies appeal process

  25. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This guide describes the interim methods and process changes that NICE has implemented as a result of the proportionate approach to technology appraisals work done between April 2022 and March 2023. It should be read alongside the relevant sections of the NICE health technology evaluations manual

  26. Percutaneous thoracic duct embolisation for persistent chyle leak (IPG755)

    Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.

  27. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

  28. Radiofrequency ablation for palliation of painful spinal metastases (IPG758)

    Evidence-based recommendations on radiofrequency ablation for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.

  29. How my experience as a patient helped shape NICE guidelines for colorectal cancer

    Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future, so I applied and was accepted to be a lay member for NICE’s colorectal cancer guideline committee.

  30. Working at the forefront of neurodegenerative disease research

    Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.

  31. Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund

    Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE publishes final draft guidance today (Wednesday 29 March 2023) recommending its use in the Cancer Drugs Fund (CDF).

  32. Guidance executive

    Guidance Executive

  33. Involving you

    There are a number of ways you can get involved in the development of our guidance.

  34. Type 2 diabetes in adults (QS209)

    This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.

  35. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  36. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  37. How to use quality standards

    How providers and commissioners can use quality standards to improve the quality of care

  38. NICE recommends 3 treatments for COVID-19 in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments, under final draft guidance published by NICE today.

  39. NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines

    NICE has today (16 February 2023) issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated.

  40. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  41. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

  42. Transvenous obliteration for gastric varices (IPG751)

    Evidence-based recommendations on transvenous obliteration for gastric varices. This involves inserting a tube with a tiny balloon on the end into a vein in the thigh or neck. The tube is then passed into the enlarged vein in the stomach (gastric varix) and the balloon is inflated to stop blood flowing into the vein. The vein is then blocked using one of several techniques. The aim is to reduce the risk of bleeding.

  43. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  44. Sharing your experiences

    this would be helpful. Read our hints and tips when preparing to be a patient expert (PDF) for more information on taking part in our...

  45. History of NICE

    rapid assessment of flu product zanamivir. First public board meeting Register to attend a public board meeting . 2000...

  46. Organisations eligible to use the framework

    Organisations that can use the NICE electronic and print content framework

  47. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.

  48. Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)

    This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.

  49. Hip fracture: admission rates (IND17)

    This indicator covers the rate of people admitted with a primary diagnosis of hip fracture per 100,000 population. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG24

  50. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.